Literature DB >> 2408526

The effect of split virus influenza vaccination on theophylline pharmacokinetics.

N Grabowski, J J May, D S Pratt, W J Richtsmeier, J S Bertino.   

Abstract

The effects of split virus influenza vaccine on the pharmacokinetics of theophylline and the in vivo and in vitro induction of interferon were studied in 23 volunteers. No effect on the total body clearance, half-life, or mean residence time of theophylline was found as a result of influenza virus vaccine. Additionally, no interferon activity was detected in vivo for as long as 24 h after vaccination. Finally, no production of interferon occurred in tonsil or peripheral lymphocyte cultures inoculated with split virus vaccine. We conclude that split virus influenza vaccine does not affect theophylline pharmacokinetics. In addition, we find no evidence that split virus influenza vaccine functions as an interferon inducer in humans.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408526     DOI: 10.1164/arrd.1985.131.6.934

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly.

Authors:  I H Gomolin
Journal:  CMAJ       Date:  1986-07-01       Impact factor: 8.262

3.  The effect of pneumococcal vaccine on the disposition of theophylline.

Authors:  G C Cupit; T H Self; W B Bekemeyer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Sex-related differences in theophylline pharmacokinetics.

Authors:  A N Nafziger; J S Bertino
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Role of viral infections in the induction of adverse drug reactions.

Authors:  M Levy
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

6.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

Review 7.  Current recommendations for the prevention and treatment of influenza in the older population.

Authors:  P A Gross
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.